Factors Associated With the Delay of Chemotherapy Initiation Among Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer
Authors:
- Jian ZhaoJZJian Zhao
- Hiba AbujaradehHAHiba Abujaradeh
- Susan MazanecSMSusan Mazanec
- Catherine M. BenderCBCatherine M. Bender
- Susan SereikaSSSusan Sereika
- Margaret Quinn RosenzweigMRMargaret Quinn Rosenzweig
- 25 July 2025
- journal article
- Published by Wolters Kluwer Health in Cancer Nursing
Abstract
Background: Neoadjuvant and adjuvant breast cancer chemotherapy have been shown to improve survival outcomes, highlighting the importance of timely therapy. Objective: The study described the time to initiation of neoadjuvant or adjuvant chemotherapy among women with early-stage breast cancer and identified correlates of delay, including demographics, social determinants of health, patient factors, and symptom distress. Methods: The study utilized baseline data from the Symptom Experience and Management of cancer Outcomes According to Race and Social Demographics of Health, a multisite, longitudinal study that racially compared the time to chemotherapy initiation with consideration of social determinants of health. Logistic regression models analyzed the factors influencing chemotherapy initiation within the recommended timeframes (35 days for neoadjuvant therapy and 60 days for adjuvant therapy) after biopsy (neoadjuvant) or surgery (adjuvant). Results: Of the 256 patients included in the study, 56.5% (n = 145), received neoadjuvant therapy, and among them, 55.2% (n = 80) initiated chemotherapy within 35 days of biopsy. In the study, 43.4% (n = 111) received adjuvant therapy, with 77.5% (n = 86) initiating chemotherapy within 60 days. In univariate analysis, patients who began neoadjuvant therapy within 35 days had significantly higher Interpersonal Support Evaluation List appraisal scores. In multivariate regression analysis, symptom distress emerged as a significant predictor of the delay in initiation of adjuvant chemotherapy. Conclusion: Social support and symptom distress are considerations in chemotherapy initiation delay. Implications for Practice: Targeted interventions to alleviate symptom distress and enhance interpersonal support may facilitate timely chemotherapy initiation.Keywords
This publication has 32 references indexed in Scilit:
- Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?Cancer Medicine, 2020
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Symptom incidence, distress, cancer‐related distress, and adherence to chemotherapy among African American women with breast cancerCancer, 2017
- Timeliness in Breast Cancer Treatment—The Sooner, the BetterJAMA Oncology, 2016
- Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast CancerJAMA Oncology, 2016
- Time to Surgery and Breast Cancer Survival in the United StatesJAMA Oncology, 2016
- Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United StatesCancer, 2015
- Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumorsJournal of Cancer Survivorship, 2014
- Social support, self‐efficacy for decision‐making, and follow‐up care use in long‐term cancer survivorsPsycho-Oncology, 2014
- Perceived helpfulness and impact of social support provided by family, friends, and health care providers to women newly diagnosed with breast cancerPsycho-Oncology, 2007